menu
    • menu

    Company profile for Sichuan Elixir Pharmaceuticals

    Sichuan Elixir-PSE
    News
    US FDA says Lilly's weight-loss drug no longer in shortage

    03 Oct 2024

    // REUTERS

    J&J to invest $2 billion for new manufacturing facility in Carolina

    02 Oct 2024

    // REUTERS

    Gilead inks licensing deals to boost lenacapivir access

    02 Oct 2024

    // Zoey Becker FIERCE PHARMA

    DATA COMPILATION
    #PharmaFlow

    Sichuan Elixir Pharmaceuticals

    Contact Supplier

    Website

    CPhI Worldwide, Milan

    Attending

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    pipeline-prospector-blog/pipeline-prospector-sept-2024-bms-wins-landmark-fda-approval-for-schizophrenia-med-sanofi-s-dupixent-okayed-for-copd

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    Key Products KEY PRODUCTS

    PharmaCompass

    Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..

    Related CompaniesRelated Companies

    About

    Specializing in natural & oncology APIs, we establish R&D and production platforms for new salt, crystal form & synthetic biology research. We cooperate with clients for IND, NDA, ANDA, 505b(2) and P-IV challenges. Exploring macromolecular APIs, we focus on Glycans & polypeptides. Expertise in XDC drugs drives innovative research & payload production. With a global registration platform & international cGMP system, we offer API CMO/CDMO services worldwide. Our strategy combines FDF and APIs. Our labs meet GMP standards with a stable R&D team, over 10 years of experience, we've delivered 20+ successful projects.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Sichuan Elixir PharmaceuticalsChina Flag
    Country
    Country
    China
    Address
    Address
    Room 2018/2019, Building M3, Huanhui Commercial Plaza, High-tech Zone, Chengdu...
    Telephone
    Telephone
    +86 2889101770, +86 2889106518
    Client Email
    Email
    sales@elixir-pharm.com
    Client Website
    Website
    http://www.elixir-pharm.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    A PHP Error was encountered

    Severity: Warning

    Message: Undefined variable $tile1

    Filename: tabs/exhibitions.php

    Line Number: 43

    Backtrace:

    File: /var/www/html/application/views/include/party/inc/tabs/exhibitions.php
    Line: 43
    Function: _error_handler

    File: /var/www/html/application/models/CmnPec.php
    Line: 1626
    Function: view

    File: /var/www/html/application/views/include/party/query.php
    Line: 575
    Function: create

    File: /var/www/html/application/views/include/party/indexNew.php
    Line: 86
    Function: include

    File: /var/www/html/application/views/commonNew.php
    Line: 1368
    Function: include

    File: /var/www/html/application/controllers/PharmaServices.php
    Line: 4590
    Function: view

    File: /var/www/html/index.php
    Line: 224
    Function: require_once

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    cphi-worldwide-milan-70313.png

    CPhI Worldwide, Milan

    Attending

    envelop Contact Supplier

    CPhI Worldwide, Milan

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/sichuan-elixir-pharmaceuticals-party-content-28544.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/sichuan-elixir-pharmaceuticals-party-content-52838.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    DMF submissions from China jump 42% as India continues to top list in Q1 2024

    DMF submissions from China jump 42% as India continues to top list in Q1 2024

    Generic drugs play a crucial role in providing access to life-saving drugs at affordable prices. To that end, drugmakers submit Drug Master Files (DMFs) or their ‘recipes for making generics’ to the US Food and Drug Administration (FDA) for review. Of these, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs.PharmaCompass has been reviewing Type II submissions for several years now. We have noticed that these filings have been increasing in recent years. There has been a 33.5 percent increase in Type II DMF submissions since Q1 2018 (when 176 Type II DMFs had been submitted). However, at 235, the first quarter (Q1) of 2024 saw only a 1.3 percent increase in DMF submissions over Q1 2023. In Q1 2023, DMF submissions had increased by 21.5 percent (over Q1 2022).Of the 235 Type II submissions received by the FDA in Q1 of this year, only 35 (or around 15 percent) had their review completed under the Generic Drug User Fee Act (GDUFA). The total number of reviews completed by the US federal agency so far this year is 129.In all, FDA received 353 Type II, III, IV, and V DMF submissions, compared to 291 in Q1 2023, an increase of 21.3 percent.View FDA DMF Filings in Q1 2024 (Power BI Dashboard, Free Excel Available)DMF submissions from India dip 1.8%; China witnesses 42% rise in filings As has been the trend, India (dubbed as the pharmacy of the world) and China filed the maximum DMF submissions, with 107 and 101 submissions respectively. However, DMFs filed by Indian companies saw a marginal dip of 1.8 percent in Q1 2024 — in Q1 2023, Indian companies had filed 109 Type II DMFs. Meanwhile, DMF filings by Chinese drugmakers increased 42.2 percent in Q1 2024, up from 71 in Q1 2023.India’s MSN Laboratories was the clear leader with 15 DMF submissions to the FDA, while China’s Sichuan Elixir Pharmaceutical came a distant second with nine submissions. Indian drugmakers Aurobindo Pharma and Global Calcium (with seven submissions each) were tied at third position. There were two players at the fifth spot — India’s Dr. Reddy’s Laboratories and China’s Zhejiang Jingsheng Pharmaceutical — as both these drugmakers registered six submissions each.View FDA DMF Filings in Q1 2024 (Power BI Dashboard, Free Excel Available) Diabetes, cancer drugs emerge as hot molecules in Q1 2024Approved in June 2020, triheptanoin is the first and only FDA-approved treatment for children and adults with long-chain fatty acid oxidation disorders (LC-FAOD). At five, triheptanoin saw the maximum DMF filings. Four of those applications have already been positively reviewed.Anti-diabetic drug sitagliptin phosphate monohydrate saw four DMF filings. Empagliflozin, the API found in Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, drew three DMF filings in Q1 2024.In the US, Jazz Pharmaceuticals’ Zepzelca (lurbinectedin) is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC). Three DMF applications were submitted for lurbinectedin. Similarly, ruxolitinib phosphate, used for the treatment of patients with intermediate or high-risk myelofibrosis, also received three DMF applications.Semaglutide — the glucagon-like peptide-1 receptor agonist that catapulted Novo Nordisk to the position of the most valuable public company in Europe — received three DMF filings. Semaglutide’s arch rival, tirzepatide, also drew three DMF filings.AstraZeneca’s Brilinta (ticagrelor) plus aspirin is currently approved in over 115 countries for the prevention of stroke, heart attack, and other events in adults with acute coronary syndrome (ACS). Ticagrelor received three DMF submissions. Vonoprazan fumarate, a first-in-class potassium-competitive acid blocker to treat acid-related diseases, also received three DMF submissions.View FDA DMF Filings in Q1 2024 (Power BI Dashboard, Free Excel Available) Eighteen DMFs filed for first time in Q1 2024 During the first quarter of this year, 14 drugs saw first time filing of DMFs. Together, these 14 drugs attracted 18 DMF filings with tirzepatide topping the list with three submissions from Chinese companies.The 14 drugs that saw first time filing were clascoterone, capmatinib hydrochloride, niraparib tosylate monohydrate, vibegron, cabozantinib sulfate, ruxolitinib hemifumarate, ripretinib, ruxolitinib, ruxolitinib mesylate, tucatinib hemiethanolate, tecovirimat, tirzepatide, tolvaptan povidone, and azilsartan.View FDA DMF Filings in Q1 2024 (Power BI Dashboard, Free Excel Available) Our viewUntil 2020, DMF submissions by Indian companies used to be double those of Chinese and American firms put together. In 2022, DMF filings from India began to dip, while submissions by Chinese companies began to rise. In the first half of 2023, there was a 46.5 percent rise in DMF submissions from China. The gap between DMF filings by India and China has narrowed down considerably this year. The reasons behind this phenomenon may be multiple. But it definitely implies that America will find it increasingly difficult to reduce its reliance on China.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2738

    https://www.pharmacompass.com/radio-compass-blog/dmf-submissions-from-china-jump-42-as-india-continues-to-top-list-in-q1-2024

    #PharmaFlow by PHARMACOMPASS
    23 May 2024
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    7-Ethyl-10-Hydroxycamptothecin

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Worldwide, Milan
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 39576

    Submission : 2024-03-11

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Sichuan Elixir Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Cabazitaxel

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Worldwide, Milan
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 39645

    Submission : 2024-03-26

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Sichuan Elixir Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Cabozantinib

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Worldwide, Milan
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 39757

    Submission : 2024-03-22

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Sichuan Elixir Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Cabozantinib

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Worldwide, Milan
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 39785

    Submission : 2024-03-26

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Sichuan Elixir Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Cytisine

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Worldwide, Milan
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 39649

    Submission : 2024-03-12

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Sichuan Elixir Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Dasatinib

    China

    USDMF, CEP/COS,